Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
作者: Jing LiuBo JinHang SuXiujuan QuYunpeng Liu
刊名: BMC Cancer, 2019, Vol.19 (1), pp.1-6
来源数据库: Directory of Open Access Journals
DOI: 10.1186/s12885-019-5915-7
关键词: AfatinibEGFRL718QLeptomeningeal metastasisNSCLC
原始语种摘要: Abstract Background The epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer has been successfully treated with tyrosine kinase inhibitors (TKIs). Acquired resistance becomes a tough issue when patients fail to respond to the third-generation TKI osimertinib. This study aimed to report a case baring acquired EGFR L858R/L718Q mutation in the central nervous system induced by osimertinib, which was successfully overcome using afatinib. Case presentation A 65-year-old female patient was diagnosed with stage IV non-small-cell lung adenocarcinoma with synchronic brain metastasis in February 2015. Before and during treatment, 416 tumor-related genes were monitored dynamically by liquid biopsies using next-generation sequencing, and the treatment strategy was...
全文获取路径: DOAJ  (合作)
影响因子:3.333 (2012)

  • overcome 克服
  • metastasis 同质蜕变
  • mutation 变种
  • having 满足条件
  • patient 有耐性的
  • subsequent 随后的
  • baring 复盖岩层
  • cerebrospinal 脑脊髓的
  • adenocarcinoma 腺癌
  • acquired 获得的